Furthermore, cytokine release syndrome (CRS) occurred in 42%–58% of patients following CD19-directed CAR-T therapy for B-cell malignancies, primarily driven by CAR-T activation and macrophage-mediated cytokine release. Here, CD19 is linked to congenital rubella syndrome.